GMP for Vaccine Manufacturers

19/20 November 2024, Hamburg, Germany

Course No. 21612



Dr. Andreas Neubert

Dr. Andreas Neubert

Klocke Holding

Dr. Jörg Weyermann

Dr. Jörg Weyermann

GSK Vaccines

Robert G. Schwarz

Robert G. Schwarz


Dr. Volker Öppling

Dr. Volker Öppling


Petra Falb

Petra Falb

AGES - Austrian Agency for Health and Food Ssafety

Dr. Robert Eskes

Dr. Robert Eskes

FAREVA Unterach

Dr. Frank Sielaff

Dr. Frank Sielaff

Hessisches Landesamt für Gesundheit und Pflege


The development and production of vaccines makes high demands on the manufacturing pharmaceutical industry. The special requirements on handling and safety with live organisms necessitate measures which exceed the requirements of classic pharmaceutical manufacturing.

Topics like the enhanced risk of cross contaminations, questions about individual safety of staff and the issues of cleaning and disinfection of rooms and equipment concern a vaccine manufacturer in a considerable scale.

Specifically, the demands of the necessary bio safety classes with negative pressure of rooms versus that of aseptic processing with positive pressure requires a well thought-out design of vaccine facilities.

Also, the safety of environment and waste disposal should receive proper attention already in the design phase. But the dedicated requirements on staff safety are also a challenge in vaccine manufacturing.

This course will give you the possibility to see the theoretical background as well as the practical implementation of GMP requirements in the vaccine production. A combination of theoretical requirements and practical case studies is the best way to learn this.

Speakers from regulatory bodies, consulting and practising experts will give you the chance to get to know the different views and you will have ample opportunity to discuss specific issues with speakers and other participants


“Vaccines are expected to be very safe” is one of the headlines in the presentation of the CBER “Vaccine safety team”. At the same time, new vaccines are needed for diseases for which currently no vaccine is available, and production technologies need improvement to deal with the shortage of certain types of vaccines. This has led to the emergence of new technologies. One of the important questions from the authorities however is “How safe are the new technologies”. There are several guidelines from the FDA and other authorities that deal with the safety of the different types of vaccines.

In the development of new technologies for the pharmaceutical and biopharmaceutical production of vaccines again the question of GMP compliance and safety is emphasised.

Furthermore, with the Quality Initiative for the 21st Century from the FDA new guidelines have been issued, which have an impact not just on the conventional pharmaceutical industry but also on vaccine manufacturers. Risk management and quality in design are essential in the implementation of new technologies and the introduction of new vaccines. Ensuring the expected safety is one of the greatest challenges of all vaccine Producers.

Target Group

The course is designed for personnel of pharmaceutical industries, their suppliers and regulatory bodies who
  • are responsible for quality control and/or quality
  • assurance in vaccine/biopharmaceutical production,
  • manage the vaccine production,
  • establish the operator protection,
  • audit vaccine manufacturers,
  • design or operate vaccine production sites.

Presentations / Certificate

The presentations for this event will be available for you to download and print before and after the event.

Please note that no printed materials will be handed out on site and that there will not be any opportunity to print the presentations on site.

After the event, you will automatically receive your certificate of participation.


GMP for Vaccine Manufacturers

Seminar Programme as PDF

GMP for Vaccines: What are the Issues?
  • Differences between vaccines and conventional products
  • Inactivated and live vaccines
  • Control of vaccine strains and cell lines
  • Risk of (cross-)contamination
  • (Bio)safety issues
The Peculiarities of Viral Vaccines
  • From viral seeds to finished products
  • Requirements for raw and starting materials
  • Efficient process and product control
  • Setting specifications adequately
  • Appropriate tests and assays for product release
  • Stability testing
  • Viral safety aspects
  • TSE compliance
  • How to deal with OOS results?
  • Requirements for early and late clinical trial phases
Modern Vaccines Part I
  • Vector vaccines
  • Plasmid-DNA vaccines
  • Related regulations
The Peculiarities of Bacterial Vaccines
  • Types of vaccines available
  • Manufacturing of classical/modern bacterial vaccines
  • Challenges in manufacturing  (quality/regulatory issues)
  • New technologies and products
Containment, Biological Safety and Product Protection
  • Containment, product safety versus environmental safety
  • Primary containment and additional measures
  • Negative pressure areas in aseptic manufacturing
  • Decontamination of facilities
  • Personnel as critical component in Containment
Virus Inactivation and Virus Removal Techniques
  • Validation of virus inactivation step
  • Virus inactivation: principles and methods
  • Virus removal Methods
  • GMP issues on virus inactivation and virus removal techniques
Validation of a Decontamination System for Production Equipment, Process Devices and Cleanrooms
  • Different gassing Systems
  • System qualification
  • Validation of a dry fog detergent
Case Study: Concept of Multipurpose Vaccine Production Facility
  • Practical issues with flow of material, personnel and waste material
  • Clean room qualification
  • Segregation of cell preparation, virus production and downstream processing
  • Change over procedures for manufacturing campaigns
Modern Vaccines Part II – GMP Inspectors‘ View
  • Regulatory expectations
  • Classic vaccines
  • Aspects for modern vaccines, e.g. mRNA and protein-based
  • Experiences from inspections
cGMP Issues for Upstream Processing
  • General GMP concerns for upstream processing
  • Raw materials and media preparation
  • Cell culture
  • Virus culture
  • Inactivation of microorganisms
Issues of Staff Safety
  • Requirements and Guidelines
  • Differences vaccines products and plasma products
  • Use of S3 Coveralls
  • Environmental health and safety challenges
  • xamples from daily Business
Case Study: Isolator Filling Line for Vaccines
  • Requirements of design
  • Issues of construction
  • Qualification challenges
cGMP Issues for Downstream Processing
  • General GMP concerns for downstream processing
  • (Ultra)filtration techniques
  • (Ultra)centrifugation techniques
  • Sterile filtration  and aseptic processing
Case Study: GMP Development and Manufacturing of Recombinant Viral Vaccines for Clinical Trials
  • Regulatory expectations for vaccine batches for phase 1/2/3 clinical Trials
  • Development vs. validation
  • Regulatory expectations for implementation of analytical methods – qualification and validation
  • Contract manufacturing of IMPDs


This course is part of the GMP Certification Programme "ECA Certified Biotech Manager" Learn more

(All prices excl. VAT). Important notes on sales tax.

* also payable by credit card
American Express Visa Mastercard

Further dates on-site
Further dates on-site
Not available
Further dates online
Further dates online
Not available
Not available

Do you have any questions?

Please contact us:
Tel.: +49 6221 8444-0

Woman with headset

Go back

Testimonials about our courses and conferences

“Fantastic course – I really enjoyed the interactive structure & greatly appreciate social activity.”

Anthony Cummins, Sebela Pharmaceuticals, Ireland
GMP Auditor Practice, September 2023


“Very well organized, information on point without being overwhelming.”

Eleni Kallinikou, Pharmathen
Live Online Trainng - Pharmaceutical Contracts - Febuary 2024


“Good overview of different types of agreements, good to see both the GMP and the legal angle”

Ann Michiels, Johnson&Johnson
Live Online Trainng - Pharmaceutical Contracts, Febuary 2024



“Well prepared presentations and good presenters. I also like the way of asking questions.”

Alexandra Weidler, Hookipa Biotech GmbH, Austria
Live Online Training – QP Education Course Module A, November 2023